Surgical and endovascular interventions in patients with rheumatological disease with vascular compromise

Intervenciones quirúrgicas y endovasculares en pacientes con enfermedades reumatológicas con compromiso vascular

Lizeth Luna, Gabriel López-Peña, Cesar Cuen-Ojeda, Ramón García-Alva, Luis H. Arzola, Christopher Ruben-Castillo, Ernesto Silerio-Pérez-Corrales, and Carlos A. Hinojosa*

Department of Surgery, Surgery and Endovascular Therapy Section, Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Mexico City, Mexico

Abstract

The advances in the field of vascular and endovascular surgery have allowed the expansion of treatment options and revascularization procedures for the clinical manifestations of rheumatological diseases that comprise vascular territories. For instance, Takayasu's arteritis might present with stenosis at different levels that require interventions in the affected vessels by the inflammatory process. On the other hand, the antiphospholipid antibody syndrome is associated with arterial and venous thromboses and demands complex and prompts interventions to avoid complications. This review article focuses and analyzes the clinical vascular manifestations of rheumatological diseases, the pathophysiology, and the treatment options that have demonstrated promising clinical outcomes in the third-level care institutions.

Key words: Rheumatological diseases. Revascularization. Antiphospholipid syndrome. Systemic lupus erythematosus. Rheumatoid arthritis.

Resumen

Los avances en el campo de la cirugía vascular y endovascular han permitido la expansión de opciones de tratamiento y procedimientos de revascularización para las manifestaciones clínicas de enfermedades reumatológicas que comprometen territorios vasculares. Como ejemplo de ellas, la arteritis de Takayasu puede presentar lesiones estenóticas a diferentes niveles, lo que puede requerir intervenciones en los vasos afectados. Por otro lado, el síndrome de anticuerpos antifosfolípidos se asocia a trombosis arterial y venosa, y demanda un abordaje complejo y oportuno para evitar complicaciones. Este artículo de revisión se enfoca y analiza las manifestaciones clínicas vasculares de las enfermedades reumatológicas, la fisiopatología y las opciones de tratamiento que han demostrado resultados prometedores y óptimos en instituciones de tercer nivel.

Palabras clave: Desórdenes reumatológicos. Revascularización. Síndrome de anticuerpos antifosfolípidos. Lupus eritematoso sistémico. Artritis reumatoide.

Correspondence:

*Carlos A. Hinojosa

E-mail: carlos.a.hinojosa@gmail.com

Date of reception: 01-01-2020

Date of acceptance: 18-02-2020

DOI: 10.24875/RMA.M20000008

Available online: 16-04-2020

Rev Mex Angiol. 2020;48(1):30-34

www.RMAngiologia.com

0377-4740/© 2020 Sociedad Mexicana de Angiología y Cirugía Vascular y Endovascular, A.C. Published by Permanyer México. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Systemic autoimmune rheumatic diseases, such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), systemic sclerosis (SS), spondyloarthropathies, and vasculitis (Takayasu's arteritis [TA]), are inflammatory disorders which can all have cardiovascular (CV) clinical manifestations, for example, atherosclerosis that may lead to blood vessels stenosis. Furthermore, autoimmune disease characterized for hypercoagulable states, for example, antiphospholipid antibody syndrome (APS) gives rise to vascular disease as recurrent venous and arterial thromboembolisms, these manifestations may, in fact, be the initial presentation of the rheumatologic condition¹. The National Institute of Medical Sciences and Nutrition (INCMNSZ) is a tertiary medical center and research facility in Mexico City that receives and treats a large number of patients with autoimmune diseases and vasculitis. Experience treating patients with RA, SLE, SS, and TA have been evaluated, and the influence of inflammatory markers during the early phase, clinical factors, and patient-related variables associated with disease progression has been analyzed, as well as the severity of disease, worsening ischemic symptoms, indications for interventions, and clinical outcomes².

Atherosclerosis

RA and SLE have long been recognized as having a significant burden of atherosclerotic CV disease^{1,3}. The other autoimmune inflammatory disorders have been less well studied given their lower prevalence, but early reports in APS and SS suggest similar increased CV risk^{4,5}. As therapies for autoimmune diseases have improved over the past several decades, increasing patient longevity, the risk of premature atherosclerosis has become more clinically evident. It is now accepted that accelerated atherosclerosis is the leading cause of morbidity and mortality in the patient with a systemic autoimmune disease⁴.

Other rheumatologic conditions that are more common in women, such as SS and APS, have also been shown to exhibit accelerated atherosclerosis^{6,7}. Inflammation and autoimmunity underscore the pathogenesis of atherogenesis seen in these conditions, similarly to RA and SLE (but possibly in varying degrees). In APS, the presence of circulating antiphospholipid antibodies (aPL) appears to be the mediator of pro-inflammatory and prothrombotic effects on the vasculature⁸.

Takayasu's arteritis

TA is a rare, systemic, and inflammatory large vessel form of vasculitis of unknown etiology that may lead to occlusion or aneurysmal degeneration of the arteries in various degrees⁹, typically involves the aorta and its branches, as well as the pulmonary arteries; the clinical spectrum ranges from asymptomatic disease to severe ischemia, with catastrophic consequences¹⁰. This entity affects with greater frequency young Asian and Latin American individuals than other ethnic groups and has a female-to-male predominance of 5.8 to 1¹¹. The natural course of TA is characterized by cycles of active and inactive phases that reflect the different inflammatory states of the arterial lesions. During the "early" phase, symptoms indicate active inflammation and during the late or chronic phase, evidence of arterial insufficiency may become clinically present^{12,13}.

Treatment strategies for these two phases are different; during the active phase, immunosuppressive and cytotoxic agents are used to control the development of inflammation, relieve symptoms, and restrict the extent of the affected arteries. The chronic phase may progress resulting in extensive arterial injury, and in some cases, the need for surgical or endovascular intervention (Fig. 1)¹³, although due to the rarity of the disease and limited experience, evidence-based consensus regarding the indications for revascularizations is lacking¹⁴.

TA is primarily treated by pharmacological therapy, but surgical and endovascular treatment may be required to treat organ ischemia, renovascular hypertension, or aneurysmal lesions. These interventions have been performed successfully to ameliorate complications that would adversely affect the quality of life or life expectancy of patients. The initial experience with endovascular procedures was promising, but more recent data suggest that endovascular interventions are associated with a higher failure rate than open vascular reconstruction¹⁵; however, the long-term outcome over several decades has rarely been described and there are no guidelines to direct the choice between open surgery and endovascular approaches. In all cases, the technique and surgical approach for revascularization must be individualized, based on the extent of the arterial lesions and performed during the late phase¹⁶.

Patients with TA who underwent interventions had a higher erythrocyte sedimentation rate at the time of the diagnosis and active smoking was associated with progression of the disease, worsening ischemic

Figure 1. Magnetic resonance angiography demonstrates complete occlusion of the left axillary artery (hollow arrow) in a young woman who required surgical revascularization for disabling the left upper extremity claudication. (*Reproduced with permission from Elsevier from Hinojosa et al.².*)

symptoms, and the need for intervention. Revascularization procedures (open surgery or endovascular) are effective at relieving symptoms; these approaches may provide benefit to this relatively young population. Lifelong follow-up is mandatory².

For example, in **figure 2A and B**, a 38-year-old female with known diagnosis of TA followed in our institution since 2000 was referred to our vascular surgery clinic with 4 months history of progressive and frequent episodes of amaurosis fugax in the left eye. A computed tomography angiography (CTA) revealed focal stenotic segments in the right common carotid artery (CCA) and internal carotid artery; near occlusion of the proximal left CCA was also present. Her physical examination was notable for bilateral carotid bruits, more accentuated on the left side. This case illustrates the clinical presentation of TA affecting both carotid arteries; open revascularization through carotid subclavian bypass grafting was successfully performed with minimal morbidity, complete resolution of symptoms, and improvement of the patient's quality of life. As conclusion with this case report, revascularization procedures when indicated should be performed while the disease is inactive and close surveillance is mandatory¹⁶. Other forms of the presentation of AT are an isolated stenotic or occluded segment of the descending thoracic and/or the abdominal aorta associated and are very uncommon and

Figure 2. A and B: computed tomography angiography, coronal view demonstrated focal stenosis in the right common carotid artery (CCA) (green arrow) and near occlusion of the proximal left CCA (red arrow). Axial view shows focal stenosis in the right internal carotid artery (black hollow arrow). (*Reproduced with permission from Elsevier from Hinojosa et al.².*)

the clinical expression is known as “middle aortic syndrome” (MAS). Manifestations depend on the lesion location and may include hypertension originating from the aortic coarctation or renovascular, buttock or lower extremity claudication, and rarely chronic intestinal angina. Its prevalence is reported below 0.000001%, with approximately 200 cases reported in the literature. As an example, a 27-year-old female with a diagnosis of TA based on the American College of Rheumatology Criteria was sent to our clinic with 1-year history of intermittent claudication in April 2012. Her physical examination was notable for diminished femoral and distal pulses bilaterally; the patient had been previously treated with immunosuppressive therapy during the inflammatory phase of the disease. A CTA revealed a stenotic lesion in the infrarenal aorta, extending to both proximal common iliac arteries (**Fig. 3A**). Given her young age and following discussions about open and endovascular approaches, an aortobiliac bypass grafting using an 18 mm × 9 mm Dacron graft through transperitoneal approach with medial visceral rotation was performed (**Fig. 3B**). She had an uneventful recovery and at 46 months from the procedure remains without symptomatology.

MAS associated with TA requiring surgical intervention remains a rare event in the western hemisphere and expanding the library of aortic reconstructions, and the experience is particularly important for improvement in decision-making, surgical techniques, and outcomes. Surgery is recommended for incapacitating symptoms during the late or chronic phase of the disease. In the two cases described in this article, *in situ* reconstruction demonstrated to be effective in treating severe claudication and durable with a mean follow-up of 63 months¹⁷.

Figure 3. A and B: computed tomography angiography three-dimensional reconstruction demonstrates the stenotic lesion in the infrarenal aorta extending to the proximal common iliac arteries bilaterally. An intraoperative photograph showing the aortobiliac reconstruction with an 18 × 9 mm Dacron graft. (Reproduced with permission from Elsevier from Hinojosa et al.².)

Antiphospholipid syndrome

The APS as aforementioned is an autoimmune disease characterized by hypercoagulable state, leading to thrombosis in the venous and arterial circulation¹⁻⁴. This disorder is associated with the presence of the lupus anticoagulants in plasma anticardiolipin antibody of immunoglobulin (Ig) G and/or IgM and anti-b-2-glycoprotein 1 antibodies². The revised classification criteria from 2006 emphasized that the presence of specific antibodies and a persistent elevation for more than 12 weeks of high titers of autoantibodies detected by the enzyme-linked immunosorbent assay and by the lupus anticoagulant assay is necessary for the diagnosis.⁹ This typically affects young individuals, and with more frequency the female gender with autoimmune diseases (e.g., SLE), and should be suspected in women with a history of repeated abortions and/or venous and arterial thrombosis⁶. APS can be primary in the absence of any other related disease (autoimmune or connective tissue disorders) or secondary in the presence of autoimmune diseases such as SLE⁶. The deep veins of the lower limbs are the most commonly affected sites^{7,8}; on the other hand, the incidence of primary arterial involvement is unknown because no literature has differentiated between thromboembolic disease from the presence of underlying atherosclerotic disease in this particular group of patients⁹. According to the literature reports, the most affected arteries are the coronary circulation

followed by the visceral vessel district, renal, retinal, and peripheral arteries², there are only five cases of aortic thrombosis reported in patients with APS¹⁰.

APS associated with limb or organ ischemia is rarely encountered and recognized in a vascular surgery practice, and little has been written regarding its therapeutic approach and clinical outcomes¹². The IN-CMNSZ also receives and treats a large number of patients with prothrombotic¹²⁻¹⁴.

Limb loss in patients with APS represents another devastating complication. Despite the technical success, the risk of recurrent thrombosis, thromboembolic events, restenosis of vessels, graft failure, and progression of the disease in these patients remains high even on optimal anticoagulation and commonly results in a high rate of limb loss in this relatively young population¹⁵. Although some authors state that an optimal anticoagulation postoperatively has shown to maintain a lower incidence in thrombosis recurrence which has led to the recommendation of lifelong anticoagulation therapy with an international normalized ratio (INR) target of 3.0¹⁵, following arterial reconstructions, we have maintained an aggressive anticoagulation regime with an INR target range from 3.0 to 3.5 and antiplatelet therapy, and patients are clinically followed closely and monitored for possible hemorrhagic complications. With respect to the conduits, we agree with Lauvao et al. in the recommendation of the use of autogenous grafts when possible and a strict perioperative and long-term anticoagulation to prevent graft failure¹⁶.

Recognized limitations of the studies in our country include the small cohort of patients and its retrospective nature, thus further clinical experience and recognition of the association of APS to vascular events (arterial and venous) and long-term follow-up are critical for understanding the natural course and establish the appropriate post-operative management and long-term follow-up.

The APS is a prothrombotic disorder that may lead to arterial involvement with less frequency than the venous circulation but has significant morbidity and limb loss rate. Arterial surgical reconstruction seems to be feasible in an attempt to salvage limbs and organs; however, further experience and research are necessary to establish the optimal anticoagulation regime and long-term management following surgical interventions.

Conclusion

Arterial involvement in rheumatological disorders is rare, but when clinically present, its management may

be complex. The experience has demonstrated that the open and endovascular approaches are effective in select clinical scenarios. Further, research including clinical trials when possible is necessary to better define the optimal approach.

Conflicts of interest

The authors have no conflicts of interest.

Ethical disclosures

Protection of human and animal subjects. The authors declare that no experiments were performed on humans or animals for this study.

Confidentiality of data. The authors declare that no patient data appear in this article.

Right to privacy and informed consent. The authors declare that no patient data appear in this article.

References

1. Cobb S, Anderson F, Bauer W. Length of life and cause of death in rheumatoid arthritis. *N Engl J Med.* 1953;249:553-6.
2. Hinojosa CA, Anaya-Ayala JE, Gomez-Arcive Z, Laparra-Escareno H, Torres-Machorro A, Lizola R. Factors associated with need for revascularisation in non-coronary arterial occlusive lesions secondary to Takayasu's arteritis. *Eur J Vasc Endovasc Surg.* 2017;54:397-404.
3. Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA. The bimodal mortality pattern of systemic lupus erythematosus. *Am J Med.* 1976;60:221-5.
4. Shoenfeld Y, Gerli R, Doria A, Matsuura E, Cerinic MM, Ronda N, et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. *Circulation.* 2005;112:3337-47.
5. Roifman I, Beck PL, Anderson TJ, Eisenberg MJ, Genest J. Chronic inflammatory diseases and cardiovascular risk: a systematic review. *Can J Cardiol.* 2011;27:174-82.
6. Mankad R. Atherosclerotic vascular disease in the autoimmune rheumatologic patient. *Curr Atheroscler Rep.* 2015;17:497.
7. Zinger H, Sherer Y, Shoenfeld Y. Atherosclerosis in autoimmune rheumatic diseases-mechanisms and clinical findings. *Clin Rev Allergy Immunol.* 2009;37:20-8.
8. Shoenfeld Y, Harats D, George J. Atherosclerosis and the antiphospholipid syndrome: a link unravelled? *Lupus.* 1998;7 Suppl 2:S140-3.
9. Vargas-Alarcón G, Zúñiga J, Gamboa R, Hernández-Pacheco G, Hesiquio R, Cruz D, et al. DNA sequencing of HLA-B alleles in Mexican patients with Takayasu arteritis. *Int J Cardiol.* 2000;75 Suppl 1:S117-22.
10. Kerr GS. Takayasu's arteritis. *Rheum Dis Clin North Am.* 1995;21:1041-58.
11. Giordano JM. Surgical treatment of takayasu's disease. *Cleve Clin J Med.* 2002;69 Suppl 2:S1146-8.
12. Pagni S, Denatale RW, Boltax RS. Takayasu's arteritis: the middle aortic syndrome. *Am Surg.* 1996;62:409-12.
13. Nazareth R, Mason JC. Takayasu arteritis: severe consequences of delayed diagnosis. *QJM.* 2011;104:797-800.
14. Kim YW, Kim DI, Park YJ, Yang SS, Lee GY, Kim DK, et al. Surgical bypass vs endovascular treatment for patients with supra-aortic arterial occlusive disease due to Takayasu arteritis. *J Vasc Surg.* 2012;55:693-700.
15. Konari I, Siminelakis SN, Baikoussis NG, Papadopoulos G, Goudevenos J, Apostolakis E. Antiphospholipid syndrome; its implication in cardiovascular diseases: a review. *J Cardiothorac Surg.* 2010;5:101.
16. Lauvao LS, Goshima KR, Leon LR Jr., Nolan PE, Hughes JD. Superficial femoral artery thrombosis as a cause for distal embolism in primary antiphospholipid syndrome. *J Vasc Surg.* 2008;48:472-7.
17. Hinojosa CA, Anaya-Ayala JE, Torres-Machorro A, Lizola R, Laparra-Escareno H. Middle aortic syndrome in Takayasu's arteritis: report of two surgical cases. *Ann Vasc Surg.* 2016;34:270.e13-7.